Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

• Hauptverfasser: Jassada Buaboonnam (Verfasst von), Supattra Rungmaitree (Verfasst von), Nuntawan Piyaphanee (Verfasst von), Sirirat Charuvanij (Verfasst von), Onsiri Pitisuttithum (Verfasst von), Katherine Copeland (Verfasst von), Chatkamol Pheerapanyawaranun (Verfasst von), Laddawan Jansarikit (Verfasst von), Suvimol Niyomnaitham (Verfasst von), Kulkanya Chokephaibulkit (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to <40 kg) and 600 mg (≥40 kg) Tixagevimab-Cilgavimab, re...